drugset / Trial / NCT00632333

Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

NCT00632333

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.

Timeline

Start
2008-02
Primary completion
2011-12
Completion
2012-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject KOC1 Vaccine 0.5 mg Subcutaneous
Subject KOC1 Vaccine 1 mg Subcutaneous
Subject KOC1 Vaccine 3 mg Subcutaneous
Subject TTK Unknown 0.5 mg Subcutaneous
Subject TTK Unknown 1 mg Subcutaneous
Subject TTK Unknown 3 mg Subcutaneous
Subject URLC10 Peptide 0.5 mg Subcutaneous
Subject URLC10 Peptide 1 mg Subcutaneous
Subject URLC10 Peptide 3 mg Subcutaneous
Subject VEGFR1 Peptide 0.5 mg Subcutaneous
Subject VEGFR1 Peptide 1 mg Subcutaneous
Subject VEGFR1 Peptide 3 mg Subcutaneous
Subject VEGFR2 Peptide 0.5 mg Subcutaneous
Subject VEGFR2 Peptide 1 mg Subcutaneous
Subject VEGFR2 Peptide 3 mg Subcutaneous
Background Cisplatin Other / unclassified 40 mg/m2
Background fluorouracil Small molecule 400 mg/m2

Indications